THCV: a new weapon against smoking?
NCT ID NCT07636356
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This study tests whether a compound from cannabis called THCV can help people who smoke daily to resist cigarettes and smoke less. 32 smokers will receive either THCV or a placebo and then take a test measuring how long they can delay smoking and how many cigarettes they smoke. The goal is to see if THCV is safe and effective for smoking cessation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 32 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Be between the ages of 21 and 65; 2. Smoke 10 or more combustible cigarettes per day; 3. Have fewer than 3 months of smoking abstinence in the past year; 4. Has self-reported ≥10 lifetime uses of cannabis products; 5. Have self-reported recent (past 3-month) use of cannabis products; 6. Agree to abstain from all other cannabinoid use during the study; 7. Agree to abstain from all other medication use during the study, other than methods of birth control as listed in inclusion criteria for female participants; 8. Agree to one of the following methods of birth control (if female), unless she or partner are surgically sterile: oral contraceptives, Contraceptive sponge, patch, double barrier, intrauterine contraceptive device, etonogestrel implant, medroxyprogesterone acetate contraceptive injection, hormonal vaginal contraceptive ring, complete abstinence from sexual intercourse. Exclusion Criteria: 1. Have current (last 12 months) DSM-5 diagnosis of substance use disorder for any psychoactive substances other than nicotine; 2. Have a lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any other psychotic disorder; 3. Have a score of 3 or greater on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening or anytime during study participation; 4. Have a positive urine screen for any substances, including cannabis 5. Have a breathalyzer reading above 0.000 g/dl; 6. Be pregnant, nursing, or planning to become pregnant while taking part in the study; 7. Have a medical condition that may interfere with safe study participation; 8. Have clinically significant abnormalities on the EKG; 9. Have evidence of renal impairment, defined by an eGFR value of \<90 ml/min; 10. Have evidence of hepatic impairment, defined by a score of ≥5 points on the Child-Pugh assessment of liver function; 11. Exceed Grade 2 laboratory or vital sign abnormalities, based on FDA Guidance Document "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; 12. Have past month use of cannabis or cannabis products; 13. Have past month use of electronic nicotine delivery system (ENDS); 14. Have use of any medications (other than methods of birth control as listed in inclusion criteria for female participants) within 14 days or 5 half-lives (whichever is longer) prior to study drug administration, and throughout the study, including medication for smoking cessation, any prescription, OTC, dietary supplements, herbal products, or vitamins; 15. Have any other circumstances that, in the opinion of the investigators, would not be a good fit for study participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Smoking cessation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Texts and wearables team up to help latinos quit smoking and get moving
- Can an AI chatbot help cancer patients kick the habit?
- Does the clock matter? scientists randomize when Quit-Smoking chatbots ping you
- Can a WhatsApp message help smokers quit?
- Can a brain scan tailor TMS to quiet cigarette cravings?
- Practice quitting: a new way to help smokers who Aren't ready to stop?